Search This Blog

Wednesday, December 9, 2015

Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS™ (Infliximab), a Biosimilar of Remicade, in Korea | Merck Newsroom Home

Samsung Bioepis’ Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck



Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS™ (Infliximab), a Biosimilar of Remicade, in Korea | Merck Newsroom Home

No comments:

Post a Comment